Search
forLearn
5 / 801 resultslearn inca- inch
learn procapil
learn Intra-cylane®
learn Inositol
Research
5 / 1000+ resultsresearch A comprehensive investigation into the molecular mechanism responsible for selective androgen receptor (SARM) tissue-selectivity
SARMs work differently in tissues due to unique interactions and structures.
research Surgical Therapies
Transplanting skin cells is a safe, effective, and affordable treatment for vitiligo.
research Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation
HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.
research Targeting cardiac hypertrophy through a nuclear co‐repressor
Targeting NCoR1 can help treat heart enlargement and dysfunction.
research 905 Dysfunction of hair follicle mesenchymal progenitors is associated with age-related hair loss
Age-related hair loss is linked to the decline and dysfunction of hair follicle stem cells.
Community Join
5 / 1000+ resultscommunity when is kintor going to start phase 3 for gt20029?
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
community Kintor long term safety phase 3
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
community Kintor's email response to me, regarding false advertising, and my proposal for them to develop a topical dut formulation with meaningful efficacy.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Kintor announcement about pyrilutamide phase 3 results in CHINA
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.